-

Gold Standard Diagnostics Announces FDA Clearance of the B. burgdorferi IgG/IgM VlsE-OspC EIA Test

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD), a Eurofins Technologies company, today announced FDA clearance of a new B. burgdorferi IgG/IgM VlsE-OspC EIA test. This test, when used in conjunction with the other FDA cleared GSD Lyme EIA tests can be used in the CDC recommended modified two-tiered testing (MTTT) algorithm.

In 2014, the CDC issued an updated recommendation for the serologic diagnosis of Lyme disease, endorsing the use of a two-tier testing algorithm that uses a second enzyme immunoassay, or EIA, in place of a western immunoblot assay.

Gold Standard Diagnostics now offers a solution for this Lyme testing algorithm, which complements GSD’s existing market-leading Lyme test portfolio. With the addition of the B. burgdorferi IgG/IgM VlsE-OspC EIA test, customers can choose which tests and algorithms best meet their laboratory and client’s needs. All six assays are designed for optimal performance and can be run on any open automation platform.

“With the addition of the B. burgdorferi IgG/IgM VlsE-OspC EIA test to the GSD Lyme product portfolio, GSD is the first and only single source company to offer Lyme testing solutions for both the Standard and Modified Two-Tiered Testing algorithms,” said Dr. Barry Menefee, infectious disease specialist at GSD. “It is important to understand the need to combine assays designed to work in concert. By offering the laboratory complete testing solutions, optimization is always met.”

ABOUT GOLD STANDARD DIAGNOSTICS, GROUP. Gold Standard Diagnostics, Group is a clinical diagnostics group comprised of Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, and NovaTec Immundiagnostica GmbH. The companies develop, manufacture and distribute a portfolio of instrumentation and diagnostic test kits to clinical laboratories around worldwide. The US GSD Inc. is headquartered in Davis, CA. Gold Standard Diagnostics is a member of the Eurofins Technologies group of companies.

References

  1. Molins CR, Sexton C, Young JW, et al. Collection and characterization of samples for establishment of a serum repository for Lyme disease diagnostic test development and evaluation.
  2. Center for Disease Control and Prevention, Morbidity and Mortality Report MMWR, Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease, Weekly / August 16, 2019 / 68(32);703.

Customers
GSD Lyme kits and other products email USSales@gsdx.us, or www.gsdx.us.

Contacts

Katherine Hays
KHays@gsdx.us
(530) 759-8000

Industry:

Gold Standard Diagnostics

Release Versions
English

Contacts

Katherine Hays
KHays@gsdx.us
(530) 759-8000

More News From Gold Standard Diagnostics

Improved Lyme Screening Assay Now FDA Cleared for Laboratory Use

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD) today announced it offers a new B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA Screen that can be used to improve workflow and conserve testing resources. This assay has demonstrated increased sensitivity for early Lyme Disease detection - up to 20% over existing available Lyme screening assays - while maintaining 98% specificity. True Lyme negative samples are eliminated prior to second-tier testing. The OspC antigen used in t...

Gold Standard Diagnostics Receives FDA 510K for Lyme IgG and IgM EIA Kits

DAVIS, Calif.--(BUSINESS WIRE)--The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results. The assays are available immediately in the US. The separate IgG and IgM assays provide laboratories the ability to offer more specific...

Gold Standard Diagnostics Multiplex Real-Time PCR Assay for SARS-CoV-2 Pathogen Detection Now Available in the US

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics Inc. today announced the EUA submission of a Multiplex Real-Time, reverse-transcriptase polymerase chain reaction (RT-PCR) assay for the direct qualitative pathogen detection of the novel coronavirus (SARS-CoV-2). The assay is available now for purchase in the U.S. Particularly in the early phase of COVID-19 infection, the direct and precise diagnostic of the pathogen is critical. PCR is the method of choice to detect acute coronavirus i...
Back to Newsroom